
Quarterly report 2024-Q1
added 05-06-2024
ShockWave Medical Revenue 2011-2026 | SWAV
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue ShockWave Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 730 M | 490 M | 237 M | 67.8 M | 42.9 M | 12.3 M | 1.72 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 730 M | 1.72 M | 226 M |
Quarterly Revenue ShockWave Medical
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 219 M | 186 M | 180 M | 161 M | - | 131 M | 121 M | 93.6 M | - | 65.2 M | 55.9 M | 31.9 M | - | 19.6 M | 10.3 M | 15.2 M | - | 11.3 M | 10 M | 7.27 M | - | 3.6 M | 2.28 M | 1.32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 219 M | 1.32 M | 69.8 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aethlon Medical
AEMD
|
574 K | $ 2.19 | 2.34 % | $ 3.42 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 10.76 | 3.26 % | $ 1.45 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.16 | 6.39 % | $ 881 M | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 12.79 | 1.51 % | $ 1.92 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Cognyte Software Ltd.
CGNT
|
443 M | $ 8.41 | 0.36 % | $ 604 M | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 71.27 | 2.13 % | $ 106 B | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 36.62 | -2.11 % | $ 1.14 B | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.69 | 6.85 % | $ 37.6 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 4.16 | 4.95 % | $ 155 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
Establishment Labs Holdings
ESTA
|
211 M | $ 65.06 | 2.49 % | $ 1.93 B | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
ClearPoint Neuro
CLPT
|
31.4 M | $ 11.2 | 1.5 % | $ 303 M | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.44 | 0.11 % | $ 121 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 2.19 | - | $ 1.33 M | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 62.11 | 1.1 % | $ 3.39 B | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
InMode Ltd.
INMD
|
358 M | $ 13.67 | 1.79 % | $ 884 M | ||
|
Abbott Laboratories
ABT
|
44.3 B | $ 111.4 | 1.32 % | $ 194 B | ||
|
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.34 | 0.77 % | $ 21.6 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.87 | 0.56 % | $ 354 M | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 266.93 | 2.18 % | $ 7.53 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 9.28 | 3.0 % | $ 715 M | ||
|
AxoGen
AXGN
|
225 M | $ 33.06 | 0.68 % | $ 1.52 B | ||
|
Align Technology
ALGN
|
4 B | $ 177.13 | 4.53 % | $ 13.3 B | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 33.64 | 2.69 % | $ 5.01 K | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Apyx Medical Corporation
APYX
|
52.8 M | $ 3.83 | 4.36 % | $ 157 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 17.3 | 1.08 % | $ 406 M | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 86.69 | 3.12 % | $ 3.01 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M |